QLG2128

Qilu Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

QLG2128 is a small molecule inhibitor targeting a specific molecular pathway relevant to its therapeutic indication.

At a glance

Generic name	QLG2128
Sponsor	Qilu Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

QLG2128 is an investigational drug in Phase 3 development by Qilu Pharmaceutical. Limited public information is available regarding its precise mechanism of action, molecular target, and clinical efficacy profile at this stage of development.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QLG2128 CI brief — competitive landscape report
QLG2128 updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI